REPORTING FROM ADA 2018
The study subjects were men, 43 years old, on average, with a mean body mass index of 26 kg/m2.
The investigators didn’t have any disclosures, and there was no industry funding for the work.
SOURCE: Aleksic S et al. ADA 2018, Abstract 10-LB.
© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
